(ii) Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver Int. 2007 Sep;27(7):954-9. Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D. Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinik Düsseldorf, Düsseldorf, Germany. sagir@med.uni-duesseldorf.de
(iii) Antiviral Research. Volume 71, Issues 2-3, September 2006, Pages 363-371. Special Issue To Honour Professor Erik De Clercq
(iv) Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. M. Manns, H. Reesink, C. Moreno, T. Berg, Y. Benhamou, Y. Horsmans, G. Dusheiko, R. Flisiak, P. Meyvisch, O. Lenz, K. Simmen, R. Verloes. Poster: LB8. AASLD.
Contact: Karen Manson, Mobile: +32-(479)-89-47-99
